Types of Primary Immunodeficiency: Which Are Treated With Stem Cell Transplant?

Primary immunodeficiencies (PIDs) are a family of more than 450 inherited disorders in which part of the immune system fails to develop or function correctly, leaving people vulnerable to infections, autoimmunity, or both. They range from severe combined immunodeficiency (SCID) — fatal in infancy without treatment — to milder antibody deficiencies managed for life with immunoglobulin replacement. Hematopoietic stem cell transplant (HSCT) is not a universal answer here; it is a genuine cure for the subset of PIDs where the defect lives in the blood-forming stem cells themselves, and it is now being extended through newer gene therapies for several more. This article walks through where the evidence is strongest, where it is emerging, and where transplant has little or no role at all.

SCID: The Original Proof That Stem Cell Transplant Can Cure an Immunodeficiency

Severe combined immunodeficiency, nicknamed "bubble boy disease" after a 1970s Texas case, is the clearest success story in this disease category. Infants with SCID are born with little or no functioning T-cell immunity and typically die within the first year or two of life from ordinary infections unless they receive a stem cell transplant. Because the defect originates in the hematopoietic stem cells, replacing them with healthy donor stem cells — ideally from a matched sibling, or otherwise a parent, unrelated donor, or cord blood — can durably restore immune function. The data are now unusually mature: an NIH-funded study found five-year survival after transplant rose from roughly 72–73% in 1982–2009 to about 87% in 2010–2018, and that among infants whose SCID was caught through newborn screening (now available across the U.S.), survival to age five reached 92.5%. The biggest driver was timing — transplanting before 3.5 months of age and before serious infection takes hold. For the ADA-deficient form of SCID, gene therapy that inserts a corrected gene into a patient's own stem cells, avoiding the need for a donor, has also reached regulatory approval in the U.S. and Europe as an alternative to allogeneic transplant.

Wiskott-Aldrich Syndrome: From Transplant to an Approved Gene Therapy

Wiskott-Aldrich syndrome (WAS), an X-linked disorder causing immune dysfunction, abnormal bleeding, and eczema, is the second PID with a genuinely strong track record. Allogeneic HSCT from a matched donor has been used successfully for decades and remains curative for many patients, though it carries real risks from conditioning chemotherapy and graft-versus-host disease that scale with how well the donor matches. The newer development is autologous gene therapy: in December 2025, the FDA approved etuvetidigene autotemcel (Waskyra), the first gene therapy for WAS, after data from a combined 27 patients treated at a research center in Milan across two open-label studies plus an expanded-access program showed a 93% reduction in severe infections and a 60% reduction in moderate-to-severe bleeding episodes versus patients' pre-treatment history. Because it uses the patient's own corrected stem cells, it sidesteps donor-matching and graft-versus-host issues, though it still requires chemotherapy conditioning and long-term safety follow-up is ongoing.

Chronic Granulomatous Disease: Established Transplant, Gene Therapy Still Investigational

Chronic granulomatous disease (CGD) impairs white blood cells' ability to kill certain bacteria and fungi, causing recurrent serious infections and granuloma formation. Allogeneic HSCT is an established option for severe or treatment-refractory disease: a large international study of 712 children and adults who underwent transplant for CGD reported a 3-year overall survival of 85.7% and event-free survival of 75.8%. Gene therapy approaches — lentiviral vector-corrected stem cells and newer prime-editing and in vivo editing platforms — are active areas of clinical investigation, with multiple trials recruiting as of 2025–2026, but none has yet reached FDA approval for CGD. Transplant, when a suitable donor is available, remains the more established curative route, while gene therapy stays in the "promising but unproven" category here.

DiGeorge Syndrome and CVID: Where Stem Cell Transplant Has Little or No Role

Not every PID belongs in the same conversation as SCID or WAS. DiGeorge syndrome (22q11.2 deletion syndrome) causes an absent or underdeveloped thymus in its most severe form, but the FDA-approved treatment for that complete athymia — Rethymic, a processed thymus tissue implant — is not a hematopoietic stem cell therapy; it implants cultured thymus tissue, not blood-forming stem cells, and stem cell transplant does not correct the underlying thymic defect. Common variable immunodeficiency (CVID), among the most frequently diagnosed PIDs in adults, is managed overwhelmingly with immunoglobulin replacement and treatment of complications; HSCT appears only in isolated case reports for patients with severe, treatment-resistant autoimmune or lymphoproliferative complications, not as standard therapy. These examples show that "primary immunodeficiency" is not one disease with one stem cell solution — appropriateness of transplant depends entirely on whether the defect lives in the stem cells themselves.

Bottom Line

Stem cell transplant has a genuinely strong, decades-deep evidence base in primary immunodeficiency — but only for the subset of conditions, led by SCID and Wiskott-Aldrich syndrome, where the problem originates in the blood-forming stem cells and early intervention via newborn screening makes a real difference. Chronic granulomatous disease sits a step behind, with established transplant outcomes and gene therapy still in trials rather than approved use. Other PIDs, including DiGeorge syndrome and CVID, are managed with entirely different approaches, and stem cell transplant is not an appropriate or evidence-backed treatment for them. Anyone evaluating transplant or gene therapy for a specific immunodeficiency diagnosis should do so with a clinical immunology or transplant specialist, since outcomes, risks, and eligibility vary enormously even within this one disease category.